Um Estudo para Investigar Sonrotoclax (BGB-11417) mais Zanubrutinib (BGB-3111) Comparado com Venetoclax mais Acalabrutinib em Adultos com Leucemia Linfocítica Crónica Anteriormente Não Tratada
Um Estudo de Fase 3, Aberto, Randomizado de Sonrotoclax (BGB-11417) mais Zanubrutinib (BGB-3111) Comparado com Venetoclax mais Acalabrutinib em Doentes com Leucemia Linfocítica Crónica Anteriormente Não Tratada
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Study Director
- Número de telefone: 8778285568
- E-mail: clinicaltrials@beonemed.com
Locais de estudo
-
-
-
Deggendorf, Alemanha, 94469
- Recrutamento
- Donauisar Klinikum Deggendorf Klinik Fur Onkologie Und Hamatologie
-
Frankfurt am Main, Alemanha, 60389
- Recrutamento
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Münster, Alemanha, 48153
- Recrutamento
- Geho Munster
-
Straubing, Alemanha, 94315
- Recrutamento
- Klinikum St Elisabeth Straubing Gmbh Mvz Klinikum Straubing Gmbh
-
-
-
-
New South Wales
-
Blacktown, New South Wales, Austrália, NSW 2148
- Recrutamento
- Blacktown Cancer and Haematology Centre
-
Concord, New South Wales, Austrália, NSW 2139
- Recrutamento
- Concord Repatriation General Hospital
-
St Leonards, New South Wales, Austrália, NSW 2065
- Recrutamento
- Genesiscare North Shore
-
-
Queensland
-
Woolloongabba, Queensland, Austrália, QLD 4102
- Recrutamento
- Princess Alexandra Hospital
-
-
Victoria
-
Clayton, Victoria, Austrália, VIC 3168
- Recrutamento
- Monash Health
-
Heidelberg, Victoria, Austrália, VIC 3084
- Recrutamento
- Austin Health
-
Malvern, Victoria, Austrália, VIC 3144
- Recrutamento
- Cabrini Hospital Malvern
-
Melbourne, Victoria, Austrália, VIC 3004
- Recrutamento
- The Alfred Hospital
-
-
-
-
-
Brasília, Brasil, 70390140
- Recrutamento
- Instituto Dor de Pesquisa E Ensino Distrito Federal
-
Porto Alegre, Brasil, 90110-270
- Recrutamento
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Salvador, Brasil, 41950-640
- Recrutamento
- Ensino E Terapia de Inovacao Clinica Amo Etica
-
São Paulo, Brasil, 05652-900
- Recrutamento
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Brasil, 01401-004
- Recrutamento
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
-
-
-
British Columbia
-
Victoria, British Columbia, Canadá, V8R 6V5
- Recrutamento
- Bc Cancer Victoria
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8V 5C2
- Recrutamento
- Juravinski Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Canadá, QC H3t 1E2
- Recrutamento
- Jewish General Hospital
-
Montreal, Quebec, Canadá, H4J 1C5
- Recrutamento
- Ciusss Nim Hscm
-
Québec, Quebec, Canadá, G1J 1Z4
- Recrutamento
- Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)
-
Sherbrooke, Quebec, Canadá, J1H 5N4
- Recrutamento
- Ciusss de Lestrie Chus
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100730
- Recrutamento
- Peking Union Medical College Hospital
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 630014
- Recrutamento
- The First Affiliated Hospital of Chongqing Medical University
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- Recrutamento
- The First Affiliated Hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510555
- Recrutamento
- Sun Yat Sen University Cancer Center Huangpu Branch
-
Guangzhou, Guangdong, China, 510000
- Ativo, não recrutando
- Zhujiang Hospital of Southern Medical University
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- Recrutamento
- The First Affiliated Hospital of Guangxi Medical University
-
-
Guizhou
-
Guiyang, Guizhou, China, 550002
- Recrutamento
- Guizhou Provincial Peoples Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150000
- Recrutamento
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Recrutamento
- Henan Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Recrutamento
- The Second Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recrutamento
- Jiangsu Province Hospital
-
Nantong, Jiangsu, China, 201203
- Recrutamento
- Affiliated Hospital of Nantong University
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Recrutamento
- The Second Affiliated Hospital of Nanchang University
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710004
- Recrutamento
- The Second Affiliated Hospital of Xian Jiaotong University
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Recrutamento
- Shandong Provincial Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200025
- Recrutamento
- Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
-
-
Sichuan
-
Chengdu, Sichuan, China, 610071
- Recrutamento
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300020
- Recrutamento
- Institute of Hematology and Hospital of Blood Disease
-
-
Yunnan
-
Kunming, Yunnan, China, 650032
- Recrutamento
- First Affiliated Hospital of Kunming Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310002
- Recrutamento
- The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
-
-
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Coréia do Sul, 13620
- Recrutamento
- Seoul National University Bundang Hospital
-
-
Seoul Teugbyeolsi
-
SeochoGu, Seoul Teugbyeolsi, Coréia do Sul, 06591
- Recrutamento
- The Catholic University of Korea, Seoul St Marys Hospital
-
SeodaemunGu, Seoul Teugbyeolsi, Coréia do Sul, 03722
- Recrutamento
- Severance Hospital Yonsei University Health System
-
Seoul, Seoul Teugbyeolsi, Coréia do Sul, 03080
- Recrutamento
- Seoul National University Hospital
-
SongpaGu, Seoul Teugbyeolsi, Coréia do Sul, 05505
- Recrutamento
- Asan Medical Center
-
-
-
-
-
Granada, Espanha, 18014
- Recrutamento
- Hospital Universitario Virgen de Las Nieves
-
Madrid, Espanha, 28041
- Recrutamento
- Hospital Universitario 12 de Octubre
-
Majadahonda, Espanha, 28222
- Recrutamento
- Hospital Universitario Puerta de Hierro Majadahonda
-
Murcia, Espanha, 30120
- Recrutamento
- Hospital Clinico Universitario Virgen de La Arrixaca
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010-3012
- Recrutamento
- City of Hope National Medical Center
-
Orange, California, Estados Unidos, 92868-3201
- Recrutamento
- Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Estados Unidos, 94304-2205
- Recrutamento
- Stanford Cancer Institute
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012-5405
- Recrutamento
- Rocky Mountain Cancer Centers (Williams) Usor
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224-1865
- Recrutamento
- Mayo Clinic Jacksonville
-
Miami, Florida, Estados Unidos, 33140
- Recrutamento
- Mount Sinai Medical Center Braman Comprehensive Cancer Center
-
Tampa, Florida, Estados Unidos, 33612-9496
- Recrutamento
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Recrutamento
- Northwestern University
-
Zion, Illinois, Estados Unidos, 60099-2676
- Recrutamento
- Midwestern Regional Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121-2429
- Recrutamento
- Ochsner Clinic Foundation
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215-5418
- Recrutamento
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905-0001
- Recrutamento
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198
- Recrutamento
- University of Nebraska Medical Center
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Recrutamento
- Columbia University Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204-2990
- Recrutamento
- Atrium Health Levine Cancer Institute (Lci)
-
Durham, North Carolina, Estados Unidos, 27705-3976
- Recrutamento
- Duke University Medical Center
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Recrutamento
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232-1309
- Recrutamento
- Upmc Hillman Cancer Center(Univ of Pittsburgh)
-
-
Texas
-
Tyler, Texas, Estados Unidos, 75702-7522
- Recrutamento
- Texas Oncology Tyler
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112-5550
- Recrutamento
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109-4433
- Recrutamento
- Fred Hutchinson Cancer Research Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226-3522
- Recrutamento
- Medical College of Wisconsin
-
-
-
-
-
Bordeaux, França, 33076
- Recrutamento
- Centre de Lutte Contre Le Cancer Institut Bergonie
-
ClermontFerrand, França, 63100
- Recrutamento
- Chu Clermont Ferrand Therapie Cellulaire and Hematolo
-
Le Mans, França, 72037
- Recrutamento
- Centre Hospitalier Le Mans
-
Lille, França, 59000
- Recrutamento
- Hopital Claude Huriez Chu Lille
-
Lyon, França, 69373
- Recrutamento
- Centre Leon Berard
-
Montpellier, França, 34090
- Recrutamento
- Chu Montpellier Hopital Saint Eloi
-
Toulouse, França, 31100
- Recrutamento
- Iuc Toulouse Oncopole
-
-
-
-
-
Almere Stad, Holanda, 1315 RA
- Recrutamento
- Flevoziekenhuis
-
Dordrecht, Holanda, 3318 AT
- Recrutamento
- Albert Schweitzer Ziekenhuis
-
Sgravenhage, Holanda, 2545 AA
- Recrutamento
- Hagaziekenhuis
-
-
-
-
-
Bologna, Itália, 40138
- Recrutamento
- Irccs Azienda Ospedaliero Universitaria Bologna
-
Florence, Itália, 50134
- Recrutamento
- Aou Careggi, Servizio Sanitario Toscana
-
Milan, Itália, 20132
- Recrutamento
- Ospedale San Raffaele
-
Milan, Itália, 20162
- Recrutamento
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
-
Padova, Itália, 35128
- Recrutamento
- Azienda Ospedaliera Di Padova
-
Roma, Itália, 00168
- Recrutamento
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Auckland, Nova Zelândia, 1023
- Recrutamento
- Auckland City Hospital
-
Auckland, Nova Zelândia, 0622
- Recrutamento
- North Shore Hospital
-
Christchurch, Nova Zelândia, 8011
- Recrutamento
- Health New Zealand Canterbury
-
Dunedin, Nova Zelândia, 9016
- Recrutamento
- Dunedin Hospital
-
Wellington, Nova Zelândia, 6021
- Recrutamento
- Wellington Regional Hospital (Ccdhb)
-
-
-
-
-
Brzozów, Polônia, 36-200
- Recrutamento
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice, Polônia, 40-519
- Recrutamento
- Pratia Onkologia Katowice
-
Krakow, Polônia, 30-727
- Recrutamento
- Pratia McM Krakow
-
Lublin, Polônia, 20-090
- Recrutamento
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw, Polônia, 50-367
- Recrutamento
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Birmingham, Reino Unido, B15 2TH
- Recrutamento
- Queen Elizabeth Hospital
-
Bournemouth, Reino Unido, BH7 7DW
- Recrutamento
- University Hospitals Dorset Royal Bournemouth Hospital
-
Leeds, Reino Unido, LS9 7TF
- Recrutamento
- St Jamess University Hospital
-
London, Reino Unido, SE5 9RS
- Recrutamento
- Kings College Hospital
-
Norwich, Reino Unido, NR4 7UY
- Recrutamento
- Norfolk and Norwich University Hospitals Nhs Foundation Trust
-
-
-
-
-
Bucharest, Romênia, 30171
- Recrutamento
- Coltea Clinical Hospital
-
Bucureti, Romênia, 022328
- Recrutamento
- Institutul Clinic Fundeni
-
ClujNapoca, Romênia, 400015
- Recrutamento
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca
-
-
-
-
-
Stockholm, Suécia, 171 76
- Recrutamento
- Karolinska Universitetssjukhuset Solna
-
-
-
-
-
Brno, Tcheca, 625 00
- Recrutamento
- Fakultni Nemocnice Brno
-
Hradec Králové, Tcheca, 500 03
- Recrutamento
- Fakultni Nemocnice Hradec Kralove
-
Olomouc, Tcheca, 77900
- Recrutamento
- Fakultni Nemocnice Olomouc
-
Ostrava, Tcheca, 708 00
- Recrutamento
- Fakultni Nemocnice Ostrava
-
PLZE, Tcheca, 323 00
- Recrutamento
- Fakultni Nemocnice Plzen
-
Prague, Tcheca, 10000
- Recrutamento
- Vseobecna Fakultni Nemocnice V Praze
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
- Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- Measurable disease by Computer Tomography/Magnetic Resonance Imaging
- Adequate bone marrow and organ function
Exclusion Criteria:
- Previous systemic treatment for CLL
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- Known central nervous system involvement
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Uncontrolled hypertension or clinically significant cardiovascular disease
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Arm A: Sonrotoclax plus Zanubrutinib
Participants will receive sonrotoclax and zanubrutinib for a fixed duration followed by observation. |
Administered orally.
Outros nomes:
Administered orally.
Outros nomes:
|
|
Comparador Ativo: Arm B: Venetoclax plus Acalabrutinib
Participants will receive venetoclax and acalabrutinib for a fixed duration followed by observation. |
Administered orally.
Outros nomes:
Administered orally.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)
Prazo: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)
Prazo: Up to approximately 16 months
|
Rate of uMRD4 is defined as the percentage of participants that achieved uMRD4 measured in both peripheral blood (PB) and bone marrow aspirate (BMA) at the post-treatment follow-up visit (PTFU1) based on next generation sequencing (NGS). |
Up to approximately 16 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
PFS in High-Risk Participants
Prazo: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Overall Survival (OS)
Prazo: Up to approximately 70 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 70 months
|
|
Overall Response Rate (ORR) as Determined by IRC
Prazo: Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response (CR), complete response with incomplete hematopoietic recovery (CRi), nodal partial response (nPR), or partial response (PR), before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by IRC. |
Up to approximately 70 months
|
|
Rate of Undetectable Minimal Residual Disease at < 10^-5 sensitivity (uMRD5)
Prazo: Up to approximately 16 months
|
Rate of uMRD5 is defined as the percentage of participants who achieved uMRD5 measured in both PB and BMA at the PTFU1 Visit based on NGS, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 16 months
|
|
Number of Participants with Adverse Events
Prazo: Up to approximately 70 months
|
Number of participants with treatment-emergent adverse events (TEAEs), adverse events of clinical interest, and serious adverse events (SAEs), including laboratory values, vital signs, and physical examination findings. |
Up to approximately 70 months
|
|
PFS Determined by Investigator Assessment
Prazo: Up to approximately 70 months
|
PFS is defined as the time from the date of randomization to the date of disease progression as determined by investigator or death due to any cause, whichever occurs first. |
Up to approximately 70 months
|
|
Complete Response Rate (CRR) by IRC and Investigator Assessment
Prazo: Up to approximately 70 months
|
CRR is defined as the percentage of participants with a CR or CRi before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier). |
Up to approximately 70 months
|
|
ORR Determined by Investigator Assessment
Prazo: Up to approximately 70 months
|
ORR is defined as the percentage of participants with a complete response or partial response, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by investigator. |
Up to approximately 70 months
|
|
Duration of Response (DOR)
Prazo: Up to approximately 70 months
|
Duration of response (determined by both IRC and investigator assessment) is defined as the time from the first qualifying response (CR, CRi, nPR, or PR) until CLL progression or death. DOR analysis will only include responders. |
Up to approximately 70 months
|
|
Time to Next Treatment (TTNT)
Prazo: Up to approximately 70 months
|
TTNT is defined as the time from randomization to the start of the next treatment for CLL. |
Up to approximately 70 months
|
|
Change from Baseline in Score on European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)-409 Questionnaire
Prazo: At baseline and up to approximately 70 months
|
Patient-reported symptoms of global health status (GHS), role functioning, and physical functioning, symptom burden and physical condition/fatigue will be measured using the European Organization for Research and Treatment of Cancer quality of life questionnaire EORTC IL-409 (an itemized version of [EORTC] quality of life questionnaire core 30 [QLQ-C30] and its CLL module CLL17). The EORTC-IL-409 consists of 17 questions answered on a 4-point scale where 1 = Not at all (best) to 4 = Very Much (worst) and 2 global health questions answered on a 7-point scale where 1 = Very poor (worst) to 7 = Excellent (best). Higher scores in GHS and functional scales and lower scores in symptom scales indicate better quality of life. |
At baseline and up to approximately 70 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Diretor de estudo: Study Director, BeOne Medicines
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Neoplasias
- Doença crônica
- Atributos da doença
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Leucemia de Células B
- Leucemia Linfóide
- Leucemia
- Condições Patológicas, Sinais e Sintomas
- Doenças hemic e linfáticas
- Leucemia Linfocítica Crônica de Células B
- Zanubrutinibe
- Venetoclax
- acalabrutinibe
Outros números de identificação do estudo
Outros números de identificação do estudo
- BGB-11417-304
- 2025-524366-21-00 (Ctis)
- 2025 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Prazo de Compartilhamento de IPD
See plan description
Critérios de acesso de compartilhamento IPD
See plan description
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .